Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 5c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of $0.28, $0.05 better than the analyst estimate of $0.23. Revenue for the quarter came in at $83.2 million versus the consensus estimate of $80.56 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Snowflake Inc. (SNOW) PT Raised to $450 at Freedom Broker
• Lululemon (LULU) PT Lowered to $115 at Freedom Broker